WEATHER ALERT January 27, 2026 (12:00 PM): Due to the recent inclement weather, we are experiencing higher than usual call volume. Your call is important to us. We strongly recommend current patients utilize the Patient Portal to reach their clinical teams with questions or to adjust their appointment if necessary. Messages received in the Patient Portal will be returned as quickly as possible. Thank you for your patience.
An orally bioavailable, allosteric Bcr-Abl tyrosine kinase inhibitor with potential antineoplastic activity. Designed to overcome resistance, ABL001 binds to the Abl portion of the Bcr-Abl fusion protein at a location that is distinct from the ATP-binding domain. This binding results in the inhibition of Bcr-Abl-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies. The Bcr-Abl fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
